Insider Buying: KORU Medical Systems (NASDAQ:KRMD) Insider Purchases $49,250.00 in Stock

Posted by George Bondi on Jun 18th, 2026

KORU Medical Systems, Inc. (NASDAQ:KRMD – Get Free Report) insider Adam Kalbermatten purchased 12,500 shares of KORU Medical Systems stock in a transaction dated Thursday, June 11th. The shares were acquired at an average cost of $3.94 per share, with a total value of $49,250.00. Following the transaction, the insider directly owned 312,500 shares in the company, valued at approximately $1,231,250. The trade was a 4.17% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

KORU Medical Systems Stock Down 1.5%

NASDAQ KRMD opened at $3.88 on Thursday. The firm has a market capitalization of $178.21 million, a P/E ratio of -77.60 and a beta of 0.43. KORU Medical Systems, Inc. has a 52 week low of $2.91 and a 52 week high of $6.61. The company has a 50-day moving average price of $4.08 and a 200-day moving average price of $4.79.

Institutional Investors Weigh In On KORU Medical Systems

Institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets increased its stake in KORU Medical Systems by 52.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 10,148 shares of the company’s stock worth $39,000 after buying an additional 3,478 shares in the last quarter. Lazard Asset Management LLC purchased a new stake in KORU Medical Systems in the 2nd quarter worth $59,000. Acadian Asset Management LLC purchased a new stake in KORU Medical Systems in the 1st quarter worth $63,000. Arrowstreet Capital Limited Partnership purchased a new stake in KORU Medical Systems in the 1st quarter worth $79,000. Finally, Invesco Ltd. purchased a new stake in KORU Medical Systems in the 2nd quarter worth $80,000. Hedge funds and other institutional investors own 58.60% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on KRMD shares. Wall Street Zen lowered KORU Medical Systems from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Weiss Ratings lowered shares of KORU Medical Systems from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 29th. Canaccord Genuity Group reissued a “buy” rating and issued a $6.00 target price on shares of KORU Medical Systems in a report on Friday, March 13th. Finally, B. Riley Financial increased their target price on shares of KORU Medical Systems from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Friday, March 13th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $7.25.

View Our Latest Stock Report on KORU Medical Systems

KORU Medical Systems Company Profile

(Get Free Report)

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.